SEARCH

SEARCH BY CITATION

References

  • Andurkar SV, Stables JP, Kohn H. (1999) The anticonvulsant activities of N-benzyl 3-methoxypropionamides. Bioorg Med Chem 7:23812389.
  • Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. (2007) Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48:13081317.
  • Beyreuther B, Callizot N, Stöhr T. (2006) Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol 539:6470.
  • Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T. (2007) Lacosamide: a review of preclinical properties. CNS Drug Reviews 13:2142.
  • Bialer M. (2002) New antiepileptic drugs currently in clinical trials: is there a strategy in their development? Ther Drug Monit 24:8590.
  • Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. (2002) Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 51:3171.
  • Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. (2007) Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 73:152.
  • Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd G. (2008) Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 49:418424.
  • Brandt C, Heile A, Potschka H, Stoehr T, Loscher W. (2006) Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 47:18031809.
  • Brodie MJ, Kwan P. (2002) Staged approach to epilepsy management. Neurology 58(Suppl 5):S2S8.
  • Cawello W, Kropeit D, Schiltmeyer B, Hammes W, Horstmann R. (2004) Food does not affect the pharmacokinetics of SPM 927 (Abstract 2.342). Epilepsia 45(Suppl 7):307.
  • Cramer JA, Ben-Menachem E, French J. (2001) Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res 47:1725.
  • Doty P, Rudd GD, Stoehr T, Thomas D. (2007) Lacosamide. Neurotherapeutics 4:145148.
  • Errington AC, Coyne L, Stöhr T, Selve N, Lee G. (2006) Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50:10161029.
  • Errington AC, Stöhr T, Heers C, Lees G. (2008) The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 73:157169.
  • Horstmann R, Bonn R, Cawello W, Doty P, Rudd D. (2002) Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927 (Abstract 2.174). Epilepsia 43(Suppl 7):188.
  • Horstmann R, Bonn R, Cawello W, Doty P, Rudd D. (2003) SPM 927 does not interact with valproic acid and carbamazepine (Abstract 1.271). Epilepsia 44(Suppl 9): 97.
  • Hovinga CA. (2003) SPM-927 (Schwarz Pharma). IDrugs 6:479485.
  • ILAE. (1981) Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489501.
  • Krauss G, Vaiciene N, Ben-Menachem E, Johnson M, Mameniskiene R, Brock M. (2007) Intravenous lacosamide as replacement for oral Lacosamide in subjects with partial seizures: a multicenter, open-label, inpatient trial examining safety and tolerability of 10- and 15-minute infusion durations. Presented at the 61st Annual American Epilepsy Society Meeting, Philadelphia, PA, November 30–December 4, 2007.
  • Kropeit D, Scharfenecker U, Schiltmeyer B, Koch B, Rudd GD, Cawello W, Horstmann R. (2006) Lacosamide has low potential for drug-drug interaction (Abstract 851). J Pain 7:S63.
  • Kwan P, Brodie MJ. (2000) Early identification of refractory epilepsy. N Engl J Med 342:314319.
  • Marson AG, Kadir ZA, Chadwick DW. (1996) New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 313:11691174.
  • Marson AG, Kadir ZA, Hutton JL, Chadwick DW. (1997) The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38:859880.
  • Sander JW. (1998) New drugs for epilepsy. Curr Opin Neurol 11:141148.
  • Sander JW, Bell GS. (2004) Reducing mortality: an important aim of epilepsy management. J Neurol Neurosurg Psychiatry 75:349351.
  • Sheets PL, Heers C, Stoehr T, Cummins TR. (2008) Differential block of sensory neuronal voltage-gated sodium channels by lacosamide, lidocaine and carbamazepine. J Pharmacol Exp Ther 326:8999.
  • Shneker BF, Fountain NB. (2003) Epilepsy. Dis Mon 49:426478.
  • Stöhr T, Kupferberg HJ, Stables JP, Choi D, Harris RH, Kohn H, Walton N, White HS. (2007) Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 74:147154.
  • Thomas D, Horstmann R, Scharfenecker U, Yates S, Nickel B, Doty P. (2007) Lacosamide has low potential for drug-drug-interaction. Poster presented at: The American Society of Consultant Pharmacists 38th Annual Meeting, Philadelphia, PA, November 14–17, 2007.